scispace - formally typeset
R

Roger J. Diegel

Publications -  2
Citations -  340

Roger J. Diegel is an academic researcher. The author has contributed to research in topics: Ixekizumab & Placebo-controlled study. The author has an hindex of 2, co-authored 2 publications receiving 206 citations.

Papers
More filters
Journal ArticleDOI

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, +90 more
- 08 Dec 2018 - 
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, +117 more
- 04 Jan 2020 - 
TL;DR: Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis and no new safety signals were identified.